FSNU.Y Stock Overview
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Fresenius SE & Co. KGaA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €7.63 |
52 Week High | €8.38 |
52 Week Low | €6.33 |
Beta | 1.08 |
1 Month Change | 9.63% |
3 Month Change | 12.70% |
1 Year Change | 1.33% |
3 Year Change | -42.80% |
5 Year Change | -44.35% |
Change since IPO | 1.37% |
Recent News & Updates
Recent updates
Shareholder Returns
FSNU.Y | US Healthcare | US Market | |
---|---|---|---|
7D | 0.4% | 2.5% | 2.7% |
1Y | 1.3% | 3.5% | 26.0% |
Return vs Industry: FSNU.Y matched the US Healthcare industry which returned 2% over the past year.
Return vs Market: FSNU.Y underperformed the US Market which returned 25% over the past year.
Price Volatility
FSNU.Y volatility | |
---|---|
FSNU.Y Average Weekly Movement | 3.3% |
Healthcare Industry Average Movement | 7.6% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FSNU.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: FSNU.Y's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1912 | 193,865 | Michael Sen | www.fresenius.com |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Fresenius SE & Co. KGaA Fundamentals Summary
FSNU.Y fundamental statistics | |
---|---|
Market cap | US$17.02b |
Earnings (TTM) | US$336.42m |
Revenue (TTM) | US$24.22b |
50.6x
P/E Ratio0.7x
P/S RatioIs FSNU.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FSNU.Y income statement (TTM) | |
---|---|
Revenue | €22.46b |
Cost of Revenue | €17.35b |
Gross Profit | €5.11b |
Other Expenses | €4.79b |
Earnings | €312.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 31, 2024
Earnings per share (EPS) | 0.55 |
Gross Margin | 22.74% |
Net Profit Margin | 1.39% |
Debt/Equity Ratio | 62.2% |
How did FSNU.Y perform over the long term?
See historical performance and comparison